Revolution Medicines, Inc. (NASDAQ: RVMD) is highlighted as one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. The company provided a financial and business update for the fiscal second quarter of 2025, reporting progress in its key drug Daraxonrasib in Phase 3 trials for pancreatic ductal adenocarcinoma and non-small cell lung cancer. Wall Street analysts have an average 12-month price target of $72 for RVMD, representing a 101.23% upside potential. Wells Fargo initiated coverage with a Buy rating and $67 price target, citing a de-risked profile and potential positive results from the Phase 3 trial in 2026. Revolution Medicines focuses on developing targeted cancer therapies for RAS-addicted cancers.

Read more at Yahoo Finance: Here’s What the Wall Street Thinks About Revolution Medicines (RVMD)